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Abstract 40 
Whole genome sequencing allows rapid detection of drug-resistant Mycobacterium 41 
tuberculosis isolates. However, the availability of high-quality data linking quantitative 42 
phenotypic drug susceptibility testing (DST) and genomic data has thus far been limited. 43 
We determined drug resistance profiles of 176 genetically diverse clinical M. tuberculosis 44 
isolates from Democratic Republic of the Congo, Ivory Coast, Peru, Thailand and 45 
Switzerland by quantitative phenotypic DST for 11 antituberculous drugs using the BD 46 
BACTEC MGIT 960 system and 7H10 agar dilution to generate a cross-validated phenotypic 47 
DST readout. We compared DST results with predicted drug resistance profiles inferred by 48 
whole genome sequencing. 49 
Classification of strains by the two phenotypic DST methods into resistotype/wild type 50 
populations was concordant in 73-99 % of cases, depending on the drug. Our data suggests 51 
that the established critical concentration (5 mg/L) for ethambutol resistance (MGIT 960 52 
system) is too high and may misclassify strains as susceptible, compared to 7H10 agar 53 
dilution.  Increased minimal inhibitory concentrations were explained by mutations identified 54 
by whole genome sequencing. Using whole genome sequences, we were able to predict 55 
quantitative drug resistance levels for the majority of drug resistance mutations. Predicting 56 
quantitative levels of drug resistance by whole genome sequencing was partially limited due 57 
 o
n
 M
arch 1, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
3 
 
to incompletely understood drug resistance mechanisms. The overall sensitivity and 58 
specificity of whole genome-based DST were 86.8 % and 94.5 %, respectively.  59 
Despite some limitations, whole genome sequencing has the potential to infer resistance 60 
profiles without the need for time-consuming phenotypic methods.  61 
Introduction 62 
Timely and accurate drug susceptibility testing (DST) of M. tuberculosis isolates is vital to 63 
prevent the transmission of multidrug-resistant strains (MDR – resistance to rifampicin and 64 
isoniazid) (1).The slow growth and stringent biosafety requirements of M. tuberculosis make 65 
obtaining a full DST profile by culture-based techniques a matter of weeks or months. In 66 
addition, culture-based DST is notoriously challenging for several drugs, e.g. pyrazinamide 67 
and ethionamide due to poor drug solubility in commonly used culture media (2). 68 
Drug resistance in M. tuberculosis is mainly conferred by chromosomal mutations in a few 69 
genes (3), making it possible to detect drug resistance by sequencing these genes or probing 70 
them by molecular hybridisation (4). Several commercial tests for the detection of resistance-71 
associated mutations are available, e.g. the GenoType MTBDRplus V2 (Hain Lifescience 72 
GmbH, Nehren, DE) (5) and the AID TB Resistance Line Probe Assay (AID GmbH, 73 
Strassberg, DE) (6). The World Health Organisation (WHO) endorses line probe assays and 74 
the Xpert® MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) for the detection of rifampicin 75 
resistance as a surrogate marker for multidrug-resistance (7, 8). These molecular tests have 76 
high sensitivities for drugs with established target(s) of resistance and for which only a few 77 
mutations are responsible for most resistance in clinico (e.g. rifampicin, isoniazid) (4). 78 
However, these molecular tests show low sensitivity for heteroresistant strains (concomitant 79 
presence of wild type (wt) and mutant or multiple different resistant variants in patient 80 
isolates), when frequencies of mutant variants drop below 5-50 % (9, 10). Furthermore, there 81 
are no commercially available rapid tests for many drugs currently/prospectively in use (e.g. 82 
bedaquiline, delamanid, linezolid, p-aminosalicylic acid) and the WHO only recently defined 83 
ad interim critical concentrations for bedaquiline and delamanid for use with the BACTEC 84 
MGIT 960 system (11, 12). 85 
A wealth of genomic data on drug-resistant M. tuberculosis has become available in the past 86 
years (13, 14). Unfortunately, quantitative phenotypic DST data are lacking for most of the 87 
genetic data sets, necessary to infer phenotypes from genotypes. In addition, DST data are 88 
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often limited as the strains were classified as susceptible or resistant using at the WHO-89 
defined critical concentration (15). There is an urgent need to link genotypic and phenotypic 90 
drug resistance readouts to obtain a better understanding of the mechanisms influencing the 91 
evolution and spread of drug resistance in M. tuberculosis (3, 16).  92 
WGS of clinical isolates allows for accurate identification of established  chromosomal 93 
mutations increasing the minimal inhibitory concentration (MIC) (13, 17, 18)  and may 94 
ensure adequate treatment in days instead of months. We compared whole genome-based 95 
drug resistance profiles with two culture-based quantitative DST methods for a total of 11 96 
drugs, including  rifampicin, rifabutin, isoniazid, all WHO group B (streptomycin, kanamycin 97 
A, amikacin and capreomycin), as well as selected group A (moxifloxacin),  group C  98 
(ethionamide) and group D (ethambutol, pyrazinamide) drugs (11).  99 
Material and methods 100 
M. tuberculosis isolates 101 
The initial data-set consisted of 189 M. tuberculosis isolates. A subset of 61 strains was used 102 
to establish the phenotypic DST methodology. These 61 strains were collected by the Swiss 103 
National Center for Mycobacteria between 2004-2015, and represent a broad spectrum in 104 
geographic origin and drug resistance profiles (19–21). We then applied the quantitative DST 105 
methodology to 125 prospectively collected clinical isolates from clinics participating in the 106 
International epidemiology Databases to Evaluate AIDS (IeDEA) (22) in Peru, Thailand, 107 
Ivory Coast and the Democratic Republic of the Congo (supplementary Table S3). Thirteen 108 
strains had to be excluded due to failed WGS (n = 4, failed library preparation due to low 109 
DNA quality), irreproducible DST results (n = 1), no growth in the 7H10 agar dilution assay 110 
(n = 3), duplication (n = 1), mixed cultures (n = 2, cross-contamination or patient infected 111 
with multiple strains) or transmission clusters (n = 2). The final set consisted of 176 strains.  112 
Phenotypic DST 113 
MGIT 960- and 7H10 agar dilution-based phenotypic DST were performed as described 114 
previously (19). Critical concentrations used for the classification of strains into 115 
resistant/susceptible aim to predict clinical outcome, i.e. treatment failure if a given strain is 116 
resistant at the critical concentration. However, critical concentrations should ideally be 117 
defined on the basis of the epidemiological cut-off (ECOFF: The highest wt MIC observed in 118 
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absence of any detectable resistance mechanism (23)), treatment outcomes and pharmako-119 
kinetic and -dynamic data. As M. tuberculosis infections are treated with combination 120 
therapy, outcome data for single drugs are difficult to obtain (24). This calls for definition of 121 
critical concentrations solely based on the ECOFF (11). We therefore classified strains as 122 
belonging to the resistotype/wt populations on the basis the detection of growth/no growth at 123 
the ECOFF derived from our data (25). Table 1 lists the ECOFFs used, supplementary Table 124 
S2 the drug concentrations tested with the MGIT 960 and 7H10 agar-dilution assays and 125 
Table 2 the genes screened for mutations with WGS. Further details on how the phenotypic 126 
DST assays were performed are available in the supplementary materials. 127 
Data analysis 128 
The categorical agreement between classification of strains into resistotype/wt populations 129 
using MGIT 960 and 7H10 agar dilution was based on detectable growth at the ECOFF 130 
(Table 1). The numerical variation between the two methods was quantified as the geometric 131 
standard deviation (SD, given with its standard error) of the ratio MIC MGIT 960/MIC agar 132 
dilution, expressed as a number of 2-fold dilutions and denoted by σ. The geometric SD was 133 
computed by fitting a log-normal distribution to the ratio MIC MGIT 960/MIC agar dilution 134 
as implemented in the R package fitdistrplus (v.1.0-9) (26). If the data was compatible with σ 135 
= 0, the geometric standard deviation could not be estimated and was defined as “not 136 
applicable” (NA). The approach is a generalization of the Bland and Altman method (27), 137 
taking censoring of the data into account. Strains for which the MGIT 960 MIC and 7H10 138 
agar dilution MIC were both left-censored or both right-censored were excluded since no 139 
information on the ratio could be derived. 140 
Goodman and Kruskal’s gamma was used to quantify the rank correlation between the two 141 
methods. No correlation could be calculated if the variance for either method was 0 and 142 
denoted with “not applicable” (NA). 143 
Distributions of wt and mutant MICs were analysed qualitatively based on the results of 144 
7H10 agar dilution. We divided the dataset into two groups: drugs for which the MIC 145 
distributions of wt and mutant strains did not overlap, and those for which MIC distributions 146 
overlapped.  147 
Sensitivities and specificities of WGS-based resistance profile inference were calculated 148 
based on the 7H10 agar dilution results for all drugs, except pyrazinamide– for which the 149 
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MGIT 960 results were used, based on  growth/no growth at the ECOFF,  derived from our 150 
data and the presence or absence of a putative resistance-associated mutation.  151 
Defining cut-offs for high/low-level MICs 152 
The therapeutic window of a drug is defined as the concentration range within which a drug 153 
is considered to be effective and safe to use (28). Mutations can increase the MIC beyond the 154 
therapeutic window and render the drug clinically ineffective. Drugs may have large 155 
therapeutic windows beyond the ECOFF. For these, MIC increases caused by mutations may 156 
still be within the therapeutic window of a drug: these strains might still be treatable by 157 
increasing the drug dose. We analysed the distribution of MICs of mutant strains, and 158 
assessed if cut-offs for low-level (within the therapeutic window) and high-level (beyond the 159 
therapeutic window) MICs were definable. There were sufficient data available to define 160 
distinct cut-offs for low/high-level MICs for isoniazid, rifampicin, streptomycin and 161 
amikacin. For mutations conferring resistance to other drugs assayed in this study, no distinct 162 
separation into resistotype populations with high/low-level MICs was possible due to wide 163 
ranges of MICs conferred by the individual mutations or the mutations conferred MICs 164 
beyond the therapeutic window. 165 
WGS and single nucleotide polymorphism (SNP) calling 166 
WGS and data analysis was performed as previously described (29) and summarised in the 167 
supplementary materials. The performance of WGS-based DST greatly depends on the 168 
availability of robust markers of resistance. We therefore focussed on a set of high-169 
confidence resistance-associated genes (3, 14, 28) (Table 2). We additionally assessed the 170 
impact of eis promotor mutations on amikacin and capreomycin resistance, as the association 171 
of mutations in the eis promotor with resistance to the aforementioned drugs has been 172 
reported but is not well established (11, 30).  173 
Ethics 174 
Local institutional review board or ethics committee approval was obtained at all local study 175 
sites. Informed consent was obtained where requested per local regulations. This project was 176 
also approved by the Cantonal Ethics Committee in Bern, Switzerland. 177 
Results 178 
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Agreement between MGIT 960 and 7H10 agar dilution phenotypic DST 179 
Table 3 and Figure 1 summarize the agreement between the semi-quantitative/quantitative 180 
MIC determination by MGIT 960 and 7H10 agar dilution in terms of classifying strains as 181 
belonging to the resistotype or wt populations as inferred by growth/no growth at the ECOFF 182 
(Table 1). Agreement was high for all drugs, except ethambutol (see below). For most drugs, 183 
the MGIT 960-based MICs were higher than the 7H10 agar dilution-based MICs. MICs 184 
obtained using the two methods were within 1-2 two-fold dilution steps of each other. The 185 
classifications into resistotype/wt populations demonstrated high rank correlations for most 186 
drugs (Table 3 and Figure 1), except for capreomycin (supplementary Figure S4) due to few 187 
strains demonstrating increased capreomycin MICs included in the study.  188 
WGS and in silico resistance profile prediction 189 
A total of 176 whole genome sequences with a median coverage of 676x (interquartile range 190 
[IQR] = 37.48) were obtained. Median mapping percentage and percentage of genome 191 
covered were 98.7 % (IQR = 0.94) and 99.4 % (IQR = 0.4), respectively. Genes involved in 192 
drug resistance demonstrated high coverages with only 0.8 % of all positions suffering from 193 
coverages below 7x (see supplementary materials). All major M. tuberculosis lineages, 194 
except lineage 7, were represented in the study (L1 = 6, L2 = 36, L3 = 11, L4 = 123, L5 = 1, 195 
L6 = 1). The strains showed a range of drug resistance profiles (Figure 2). Based on the set of 196 
analysed genes (Table 2), 25 strains were predicted to be fully susceptible against all assayed 197 
drugs, 59 strains were mono-/poly-resistant, 91 strains  were MDR and two strains were 198 
predicted to be extensively drug-resistant (XDR: isoniazid, rifampicin, fluoroquinolone and 199 
aminoglycoside resistant). 200 
Drug resistance profile prediction by WGS vs. phenotypic DST  201 
After exclusion of known phylogenetic markers not involved in resistance, WGS-based 202 
resistotype prediction using a defined set of target genes (Table 2) was highly congruent with 203 
the categorical classification based on the phenotypic DST for most drugs (Table 3, Table 4, 204 
Figure 1). Based on the in silico resistotype prediction, the MICs of mutant and wt strains 205 
frequently followed a Gaussian distribution. Yet, the same resistance marker may confer 206 
different MICs in different strains (supplementary Figures S1C, S2C, S3C, S8C, S9C S10C). 207 
In some cases, the increase in the MIC conferred by a certain resistance mutation fell within 208 
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the distribution of the wt MIC (e.g. for gidB, eis promotor mutations, supplementary Figures 209 
S3C S6C).  210 
Distinct wt and mutant MIC distributions 211 
MIC distributions of wt and mutant strains were well separated for rifampicin, rifabutin, 212 
isoniazid, kanamycin A, amikacin, capreomycin, streptomycin and pyrazinamide, indicating 213 
that the resistance markers used had a high positive predictive power (88.9 % overall positive 214 
predictive power of associated with MIC increases). For streptomycin, two strains harboured 215 
no mutations in the target genes, yet demonstrated high-level phenotypic resistance 216 
(supplementary Figure S3C). 217 
Overlapping wt and mutant MIC distributions 218 
MIC distributions of wt and mutant strains overlapped for ethambutol, moxifloxacin and 219 
ethionamide (Figure 3). For ethambutol and ethionamide, overlapping MIC distributions of 220 
wt and mutant strains were associated with a large number of polymorphisms in resistance-221 
conferring genes (ethambutol resistance: 22 polymorphisms in embB, ethionamide resistance: 222 
28 in ethA, 3 in inhA, 6 in inhA promoter). Solubility issues with ethionamide led to 223 
quantitative differences in MGIT 960 vs. 7H10 agar dilution-based DST (Table 3, Figure 1). 224 
The overlap in MIC distributions between wt and strains carrying an embB mutation was 225 
reduced by adjusting the critical concentration for ethambutol resistance from 5 mg/L to 2.5 226 
mg/L (MGIT 960). However, there was variability in the MICs for the same mutation (e.g. 227 
MIC EmbB M306I/V in 7H10 agar dilution: 4-16 mg/L –supplementary Figure S2C). 228 
Moxifloxacin resistance was rare (n = 9, MGIT 960, critical concentration 0.25 mg/L) and 229 
MIC distributions of mutant strains partially overlapped with those of wt. Sensitivity of the 230 
genome-based moxifloxacin resistance prediction was 80.0 % (Table 4). 231 
Defining cut-offs for high-/low-level MICs 232 
Isoniazid 233 
Mutations in the promoter of inhA caused low-level MICs <1 mg/L (7H10 agar dilution), 234 
compared to strains harbouring mutations in katG or combinations of inhA promoter and 235 
katG mutations which demonstrated MIC levels ranging from >1 mg/L to >32 mg/L in 7H10 236 
agar dilution (supplementary Figure S8C). Defining cut-offs for low- (≤1 mg/L for MGIT 237 
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960/7H10 agar dilution) and high-level (>1 mg/L MGIT 960/7H10 agar dilution) isoniazid 238 
MICs is warranted. 239 
Rifampicin/Rifabutin 240 
Most mutations in rpoB increased the MIC for rifamycins beyond the therapeutic window 241 
(peak serum concentration 10 mg/L (28, 31)). However, some rare rpoB mutations (e.g. 242 
RpoB L452P, H445L – supplementary Figure 9C) demonstrated MICs within the therapeutic 243 
window. Defining cut-offs for low- and high-level MICs may thus be justified.  244 
For rifampicin, cut-offs for low-/high-level MICs were ≤4/2 mg/L for MGIT 960/7H10 agar 245 
dilution and >4/2 mg/L for MGIT 960/7H10 agar dilution, respectively. 246 
For rifabutin, our data suggests a cut-off for low- and high-level MICs of ≤0.4/0.25 or 0.5 247 
mg/L for MGIT 960/7H10 agar dilution and >0.4/0.25 or 0.5 mg/L for MGIT 960/7H10 agar 248 
dilution, respectively. 249 
Mutations in rpoB conferring resistance to rifampicin and rifabutin showed highly correlated 250 
increases (Figure 4) of MICs beyond the therapeutic window for most rpoB mutations  Figure 251 
3 and supplementary Figure S9C & S10C), indicating that both drugs are rendered clinically 252 
ineffective by the mutations identified in the dataset (32) and cannot substitute each other.  253 
Amikacin 254 
Few strains had mutations in the regions of rrs relevant for amikacin resistance or the eis 255 
promoter (n=12). Mutations in rrs were associated with high-level (>128 mg/L in 7H10 agar 256 
dilution) MICs. With regards to the eis promotor, only the C-14T mutation increased the MIC 257 
and led to low-level (2-4 mg/L in 7H10 agar dilution) MICs. The definition of a cut-off for 258 
low- (≤ 4 mg/L for MGIT 960/7H10 agar dilution) and high-level (4 mg/L for MGIT 259 
960/7H10 agar dilution) amikacin MICs may be warranted.  260 
Streptomycin 261 
Certain mutations lead to MICs well beyond the therapeutic window (28) of streptomycin 262 
(e.g. RpsL K43R, MIC 7H10 agar dilution >128 mg/L, supplementary Figure S3C). On the 263 
other hand, gidB mutations increase the MIC only moderately (MIC 7H10 agar dilution 1-4 264 
mg/L, supplementary Figure 3C). Mutational combinations in gidB, rrs, rpsL were common 265 
and produced a range of different MICs. Despite the distribution of MICs conferred by 266 
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combinations of mutations, there were distinct mutations that systematically lead to MICs 267 
beyond the therapeutic window, e.g. RpsL K43R. Defining a cut-off for low-level (MGIT 268 
960 ≤4 mg/L, 7H10 agar dilution ≤4-8 mg/L) and high-level streptomycin MICs (MGIT 960 269 
>4 mg/L, 7H10 agar dilution >4-8 mg/L) is warranted. 270 
Discussion 271 
The results of MGIT 960 and 7H10 agar dilution-based phenotypic DST methods were 272 
highly correlated and suitable to separate the resistotype from the wt populations. Based on 273 
phenotypic DST results and WGS, we were able to define cut-offs for high- and low-level 274 
MICs for isoniazid, rifampicin, streptomycin and amikacin. Defining such cut-offs may serve 275 
as starting points for correlating mutational, DST and pharmaco-kinetic/dynamic data to gain 276 
more insight into the influence of individual mutations on treatment outcomes, especially in 277 
the light of e.g. increased drug dosing.  278 
Our data suggest that the current WHO-defined critical concentration for phenotypic DST of 279 
ethambutol by MGIT 960 (5 mg/L) is too high and may misclassify strains as belonging to 280 
the wt population when compared to the 7H10 agar dilution-based classification. Given the 281 
narrow therapeutic window for ethambutol, this may lead to mistreatment due to presumed 282 
ethambutol susceptibility. After adjusting the ECOFF to 2.5 mg/L for MGIT 960, we 283 
observed a strong improvement of the categorical agreement between MGIT 960- and 7H10 284 
agar dilution-based classification into resistotype/wt populations. 285 
The mutations identified by WGS had a high predictive power to classify strains as belonging 286 
to the resistotype population. However, the predictive power depends on a number of factors. 287 
For instance, the increase in MIC conferred by an identical mutation can vary greatly in 288 
different strains (e.g. EmbB M306I/V, RpsL K88R) (33). Such variation may be clinically 289 
relevant if there is a significant overlap between the MICs of mutant and wt strains (23), as 290 
was the case for strains harbouring mutations in genes associated with ethionamide, 291 
ethambutol and streptomycin (e.g. gidB) resistance. . Furthermore, it is difficult to classify 292 
strains as part of resistotype or wt populations if the MIC increase lies within the therapeutic 293 
window of a drug. The overlap between MICs of mutant and wt strains is confounded by the 294 
fact that we only screened for mutations in genes which had previously been associated with 295 
drug resistance. We might thus have missed possible resistance-conferring mutations in other 296 
genes. Additionally, WGS will always produce distributions of coverages, which in term will 297 
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inevitably lead to certain regions in the genome suffering from low coverage, preventing the 298 
detection of mutations. However, in cases where we observed elevated MICs without any 299 
mutations detected the target genes, coverage issues could not explain the absence of any 300 
mutations. Furthermore, the strain genetic background (34), non-mutational mechanisms (e.g. 301 
modulation of gene expression) (35), as well as drug efflux mechanisms (36) may contribute 302 
to the variability in increase of the MIC conferred by resistance mutations.  303 
The predictive power of mutations in target genes also depends on removing phylogenetic 304 
markers not involved in increasing MICs. Separating phylogenetic from resistance-associated 305 
markers works well for essential (highly conserved) genes such as rpoB, rpsL, rrs but is 306 
problematic in non-essential genes involved in the conversion of prodrugs into their active 307 
forms like pncA (pyrazinamide), ethA (ethionamide) or in genes that generally exhibit higher 308 
numbers of polymorphisms e.g. embB. Of note, the embABC operon is highly polymorphic, 309 
harbouring more polymorphisms than expected by chance (mutations in embABC operon = 310 
81, expected = 44.8, p = 9.174e-07, binomial test). Mutations conferring increased ethambutol 311 
MICs  (37) will therefore inevitably evolve in the presence of phylogenetic SNPs and may 312 
interact epistatically to produce the variability in MICs we observed for wt strains and for the 313 
most common marker associated with increased ethambutol resistance MICs, embB 314 
M306I/V. The embABC operon is involved in the biosynthesis of decaprenylphosphoryl-β-d-315 
arabinose, which is an integral component of the mycobacterial cell wall. The cell envelope 316 
interacts with the host immune system and the high levels of diversity of these genes might 317 
be the product of diversifying selection due to host immune pressure. The influence of 318 
polymorphisms in the embABC operon on MICs in general is supported by the observation 319 
that sub-inhibitory concentrations of ethambutol lower the MICs for isoniazid, rifampicin and 320 
streptomycin (38). Even small changes in activity of the decaprenylphosphoryl-β-d-arabinose 321 
biosynthetic and utilisation pathway might thus alter cell wall permeability and influence 322 
MICs of several drugs. 323 
Similarly, in the case of increased streptomycin MICs, the RpsL substitution K88R exhibited 324 
a wide range of MIC increases, partially within the therapeutic window of the drug. 325 
Streptomycin was the first effective antituberculous drug discovered (39) and has been used 326 
for decades. The long-term use has produced complex resistance profiles with multiple 327 
mutations known to increase streptomycin MICs on their own (e.g. in gidB, rpsL, rrs) 328 
occurring concomitantly, producing wide ranges of MICs. Furthermore, many strains with 329 
increased streptomycin MICs displayed MDR/XDR phenotypes. Mutations conferring 330 
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increased streptomycin MICs are frequently found in backgrounds which have mutations in 331 
genes affecting the information pathway (DNA -> RNA -> proteins) – e.g. gyrA (DNA 332 
gyrase), rpoB (DNA-dependent RNA polymerase), rrs (ribosomal RNA). The simultaneous 333 
presence of multiple MIC increasing mutations may alter the adaptive landscape (40, 41). In 334 
addition, non-mutational processes (e.g. alteration of gene expression) may compensate for 335 
fitness costs of drug resistance and at the same time alter the MIC for the drug (35). This has 336 
not been demonstrated for streptomycin resistance in M. tuberculosis, but it seems possible 337 
that compensation of fitness costs in MDR phenotypes might alter the MIC for streptomycin 338 
(40), considering that streptomycin is not part of the current standard treatment regimen and 339 
selection for high-level streptomycin MICs is relaxed.  340 
Concerning eis promoter mutations and aminoglycoside resistance, there is mounting 341 
evidence that the eis C-14T promotor mutation may confer clinically relevant increases in 342 
amikacin MICs, especially in the light of the revised critical concentrations for amikacin (2 343 
mg/L, 7H10 agar dilution) [11]. 344 
We observed an overrepresentation of lineage 4 and 2 strains in our sample set. The strain set 345 
used to establish the methodology was collated with a specific aim to include drug-resistant 346 
strains and given the frequent association of lineage 2 and 4 with drug-resistance (42, 43), the 347 
observed skew is not surprising. Furthermore, lineage 2 and 4 strains are also frequently 348 
isolated at the collection sites of the strain set used to apply the methodology (Ivory Coast, 349 
Peru and Democratic Republic of the Congo). Similarly, increased MICs for a number of 350 
drugs (amikacin, capreomycin, kanamycin, moxifloxacin) was rare, reflecting the scarcity of 351 
pre-XDR/XDR phenotypes in Switzerland and at the sites of prospective sampling.  352 
With 63.6 % – 80.8 %, sensitivities were low (44) for a number of drugs (i.e. for amikacin, 353 
moxifloxacin, pyrazinamide) (table 4), but were comparable to other studies not employing a 354 
database of pre-defined resistance mutations (14, 17, 45). The observed low sensitivities for 355 
some drugs were either due to few strains belonging to the resistotype population included in 356 
the dataset, the presence of additional resistance mutations in genes not assessed or due to 357 
unknown resistance mechanisms and not due to low coverages prohibiting the detection of 358 
mutations. The use of a curated SNP-database containing high-confidence drug-resistance 359 
mutations would improve sensitivity for some drugs where additional targets, less well 360 
associated with MIC increases, are known (44, 46). However, reliance on a predefined 361 
resistance mutation database comes at the cost of reduced sensitivity. After known 362 
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phylogenetic mutations have been removed, it is important to treat any mutation in known 363 
target genes as potentially involved in drug resistance. In cases where previously unknown 364 
mutations (i.e. neither known to increase MICs, nor a known phylogenetic SNP) in 365 
resistance-related genes are detected, genetic engineering and targeted DST is necessary to 366 
confirm or reject the drug-resistance conferring nature of a novel mutation to achieve high 367 
sensitivities and specificities for whole genome sequencing-based DST. 368 
Generating high-quality quantitative DST data using diverse M. tuberculosis strains is 369 
important to accurately define the ECOFF and subsequently guide treatment decisions. The 370 
two quantitative DST methods employed are difficult to standardize across laboratories, 371 
technically demanding and at best challenging to scale up. Microtiter plate-based quantitative 372 
DST methods (47, 48) have the potential to aid in the generation of more high quality DST 373 
data due to their standardized formulation and relative ease of application compared to 374 
established methods. 375 
In conclusion, we demonstrate that MGIT 960 and 7H10 agar dilution-based phenotypic DST 376 
provide highly congruent classifications of strains into resistotype or wt populations. WGS 377 
has high predictive power to infer resistance profiles without the need for time-consuming 378 
phenotypic methods. Limitations due to overlapping distributions of wt and resistotype MICs, 379 
varying MICs for the same mutations in different strains, presence of phylogenetic markers in 380 
resistance-associated genes and rare resistance markers with low frequencies will likely be 381 
resolved by on-going large-scale projects (e.g. ReSeqTB and others (15, 49)) combining 382 
phenotypic DST with WGS of thousands of M. tuberculosis isolates. Our findings, together 383 
with those of on-going studies will pave the way for the replacement of phenotypic DST with 384 
drug resistance profile prediction based on WGS in the coming years. 385 
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Tables 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
  417 
Table 1 Epidemiological cut-offs (ECOFF) used for 7H10 agar 
dilution and MGIT 960 phenotypic DST, derived from wild-type 
MIC distributions determined in this study. The values given in 
parentheses are the critical concentrations recommended by 
the WHO in 2014 [22]. 
Antibiotic 
ECOFF  
agar 
dilution 
(mg/L) 
ECOFF 
MGIT 
960 
(mg/L) 
Ethionamide 1 (5) 5 
Ethambutol 2 (5) 5 
Capreomycin 4 2.5 
Streptomycin 0.5 (2) 1 
Kanamycin A 2 (5) 2 (2.5) 
Amikacin 1 (4) 1 
Moxifloxacin 0.25 (0.5) 0.25 (0.5) 
Isoniazid 0.125 (0.2) 0.1 
Rifampicin 0.5 (1) 1 
Rifabutin 0.0625 0.1 
Pyrazinamide NA 100 
 
Table 2 List of genes implicated in drug resistance in M. tuberculosis which were 
screened for polymorphisms by WGS. List adapted from [3, 12, 23]. 
Drug Target gene(s) 
Ethionamide ethA, inhA, inhA promoter 
Ethambutol embB 
Capreomycin rrs, eis promoter, tlyA 
Streptomycin rrs, gidB, rpsL 
Kanamycin A rrs, eis promoter 
Amikacin rrs, eis promoter 
Moxifloxacin gyrA 
Isoniazid katG, inhA promoter 
Rifampicin/rifabutin rpoB 
Pyrazinamide pncA, pncA promoter 
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 424 
 425 
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 428 
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 432 
 433 
 434 
 435 
Figure legends 436 
Figure 1 437 
Method agreement between phenotypic DST performed with MGIT 960 and 7H10 agar 438 
dilution represented as Bland-Altman plots for all drugs tested in this study. 439 
Figure 2 440 
Maximum likelihood phylogeny of 176 M. tuberculosis strains based on 20510 variable 441 
positions. Reference strains labeled with green tip labels. Main lineages are highlighted as 442 
follows: red L4, purple L3, blue L2, pink L1, green L6, brown L5. Scale bar indicates number 443 
of substitutions per site. Phylogeny rooted on M. canettii. Colored bars indicate resistance 444 
Table 4 Sensitivity and specificity of the genome-based drug resistance profile 
prediction using the 7H10 agar dilution-based categorical classification as the 
gold standard for all drugs except pyrazinamide, for which the MGIT 960 
categorical classification was used. 
Drug Sensitivity (%) Specificity (%) 
Ethionamide 75.0 92.9 
Ethambutol 89.6 94.2 
Capreomycin 75.0 94 
Streptomycin 68.0 92.1 
Kanamycin A 83.3 98.8 
Amikacin 63.6 96.9 
Moxifloxacin 80.0 90.2 
Isoniazid 93.6 96.8 
Rifampicin 100 94.0 
Rifabutin 98.9 94.0 
Pyrazinamide 80.8 88.9 
 
 
 
 
 
Table 3 Summary statistics of the method agreement between 7H10 agar dilution- 
and MGIT 960-based phenotypic DST for all drugs assayed in this study. 
Antibiotic n 
Categorical 
agreement (%) 
SD of  
log2(MIC MGIT 960/MIC 
agar dilution) γ 
Ethionamide 56 95 1.9 ± 0.3 0.91 
Ethambutol 171 73 1.9 ± 0.5 0.94 
Capreomycin 56 98 1.5 ± 0.5 0.65 
Streptomycin 56 93 1.5 ± 0.3 0.98 
Kanamycin A 56 98 1.2 ± 0.2 0.8 
Amikacin 174 98 1.4 ± 0.6 1 
Moxifloxacin 173 99 1 ± 0.2 1 
Isoniazid 173 96 1.2 ± 0.1 1 
Rifampicin 174 99 NA 1 
Rifabutin 56 96 0.8 ± 0.1 0.98 
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mutations per gene and within a distinct column (gene) each colored bar represents a distinct 445 
mutation. Black bars indicate no mutation, i.e. wt. 446 
 447 
Figure 3 448 
Histograms of MICs (7H10 agar dilution) for all drugs assayed in this study 449 
 450 
Figure 4 451 
Correlation between 7H10 agar dilution MICs for rifampicin and rifabutin  452 
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